Pilot Study of the Contribution of Fractional Exhaled Nitric Oxide as a Prognostic Marker of Response to Anti-PD-L1 Immunotherapy in Non-small Cell Lung Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Based on the use of the patient's natural defences, immunotherapy mobilizes the immune system to recognize and destroy cancer cells, and it has revolutionized the treatment of lung cancer. However, the effectiveness of immunotherapy varies from patient to patient. At present, we have no weak markers to predict with certainty the efficacy of immunotherapy treatment in a given individual. Current scientific data identifies a number of molecules produced by the cancer cells and their environment which can be detected by various means (blood tests, breath analysis, etc.). The aim of this study is to understand whether the amount of nitric oxide (NO) present in the breath is a more accurate predictor of response to immunotherapy. Participation in this study involves breath testing (to measure FeNO (Fractional exhaled Nitric Oxide)) before receiving the first infusion of immunotherapy, and at the follow-up visit after the 4th course of immunotherapy.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Rozpoznany zaawansowany rak płuca (z przerzutami)
- •Pacjent, który wcześniej nie otrzymywał leczenia raka płuca
- •Potwierdzenie, że komórki raka wykazują cechy podatne na immunoterapię (PD-L1 > 50%)
- •Wiek powyżej 18 lat
- •Zdolność do oddychania w specjalne urządzenie do pomiaru tlenku azotu
- •Mówienie i czytanie po francusku
✗ Disqualifies
- •Wcześniejsze leczenie chemiczne lub immunologiczne raka płuca
- •Stosowanie kortykosteroidów w ciągu ostatnich 15 dni przed badaniem
- •Stosowanie kortykosteroidów do wdychania w momencie włączenia do badania
- •Konieczność stałego tlenu (24 godziny na dobę)
- •Przeciwwskazania do immunoterapii
- •Ciąża, okres połogu lub karmienie piersią
- •Osoby pod opieką sądową
- •Brak zgody pacjenta na uczestnictwo
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 10, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Chu Dijon Bourgogne
Dijon, France
Trial contact
Marjolaine GEORGES
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/11/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.